Lesson 5 — What Synthetic Biology Can Already Do

Understanding the Complex: What Is Synthetic Biology?

---

In 2003, Jay Keasling stood in front of his laboratory at UC Berkeley and made a bet he wasn't sure he could win.

Artemisinin — the most effective treatment for Plasmodium falciparum malaria — cost more than most malaria patients could afford, because the only way to produce it was to grow and harvest Artemisia annua plants, extract and purify the compound, and ship it through unreliable supply chains. Keasling believed he could rebuild the entire synthesis pathway in yeast. Not insert a single gene, but rewire the metabolism of a microorganism to run an entire series of chemical reactions that would produce artemisinic acid — the precursor that pharmaceutical manufacturers could convert into artemisinin.

The project took ten years. It involved more than a dozen different enzymes, multiple rounds of genetic circuit redesign, extensive protein engineering, and a collaboration with the Bill & Melinda Gates Foundation and the nonprofit Institute for OneWorld Health. In 2013, the Swiss pharmaceutical company Sanofi began manufacturing semi-synthetic artemisinin at scale.

The price of artemisinin fell by roughly half. The supply stabilized.

It was one of the most consequential demonstrations in the history of synthetic biology — proof that the approach could work, at scale, for a product that mattered, in the real world.

---

Medicine is the most advanced application domain, but not the only one. Here is a snapshot of where the field currently stands.

Protein production. Beyond insulin and artemisinin, microorganisms are now used to produce a wide range of therapeutic proteins: growth hormones, blood clotting factors, monoclonal antibodies, vaccines. The COVID-19 mRNA vaccines drew on decades of research into lipid nanoparticles and modified nucleosides — tools developed in part by researchers working in what would later be called synthetic biology. The field contributed to one of the fastest vaccine development timelines in history.

Materials. Bolt Threads, a California-based company, produces spider silk proteins in yeast and processes them into fibers. Spider silk is stronger than steel at the same diameter, elastic, biodegradable, and essentially impossible to harvest from spiders at scale (spiders are territorial and carnivorous — spider farms don't work). Synthetic spider silk is not yet competitive with nylon on price, but it exists, and it works. Bioleather — animal-free leather grown from mycelium or collagen-producing yeast — is in commercial production at small scale. Indigo Agriculture uses microbial seed coatings to reduce nitrogen fertilizer use in corn.

Biosensors. Bacteria can be engineered to produce a detectable signal — light, color change, electrical output — in the presence of specific molecules. Applications include detecting heavy metal contamination in water, identifying infections without a laboratory, and monitoring gut health. These are early-stage, but the proof of concept is solid.

Energy. Biofuels from engineered microorganisms — ethanol from cellulose, diesel-equivalent hydrocarbons from fatty acids — have been produced at pilot scale. The economics remain challenging against cheap petroleum, but the technical capability exists.

Biocomputing. This is the most speculative active area. Researchers have demonstrated biological "logic gates" — genetic circuits that perform simple Boolean operations (AND, OR, NOT). In principle, cells could be programmed to perform computations — detecting multiple inputs and responding with complex behaviors. This has potential applications in living diagnostics and smart drug delivery, but practical applications at useful complexity remain years away.

---

It is worth being honest about what "works" means in this context.

Most of the applications above are real — they function in the lab and, in several cases, at commercial scale. But scaling biology is hard. Fermenters are expensive. Microorganisms that produce useful compounds at lab scale often behave differently in industrial fermenters where conditions are less controlled. Purification adds cost. Regulatory approval takes years. The gap between "published in Nature" and "available at a pharmacy" can be a decade or more.

This is not a reason to dismiss the field. Artemisinin is real. Biopharmaceuticals are a $300 billion industry. The trajectory is clear. But it is a reason to maintain appropriate skepticism about timelines — and to resist the tendency, common in technology reporting, to mistake a laboratory demonstration for an imminent product.

Synthetic biology has already changed medicine. It is beginning to change materials. Whether it changes energy, agriculture, and manufacturing at the scale some proponents project is a question the next twenty years will answer.

---

Next lesson: Limits, Risks, Reality Check — what makes biology harder to engineer than it looks, and what the biosecurity stakes actually are.

---

Reading time: approx. 10–11 minutes